Roth MKM Maintains Immunic(IMUX.US) With Buy Rating, Cuts Target Price to $26

robot
Abstract generation in progress

Roth MKM has reiterated its Buy rating for Immunic (IMUX.US) but has reduced the target price to $26. This adjustment reflects a revised outlook from the analyst firm while still maintaining a positive stance on the company’s stock.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin